Cidofovir
Vistide ® |
| Usual
Diluents |
| NS |
| Standard
Dilutions [Amount of drug]
[Infusion volume] [Infusion rate] |
[Prescribed
dose] [100ml] [60 minutes]
Note: follow
chemotherapy handling precautions - See package insert
for relevant warnings.
Handling
and Disposal
Due to mutagenic properties of cidofovir,
adequate precautions including the use of
appropriate safety equipment are recommended for
the preparation, administration, and disposal of
VISTIDE. The National Institutes of Health
presently recommends that such agents be prepared
in a Class II laminar flow biological safety
cabinet and that personnel preparing drugs of this
class wear surgical gloves and a closed front
surgical-type gown with knit cuffs. If VISTIDE
contacts the skin, wash membranes and flush
thoroughly with water. Excess VISTIDE and all
other materials used in the admixture preparation
and administration should be placed in a
leak-proof, puncture-proof container. The
recommended method of disposal is high temperature
incineration.
| The
Class II Biological Safety Cabinet is
designed with inward air flow at a
velocity to protect personnel (75-100 lfpm),
HEPA-filtered downward vertical
laminar airflow for product protection,
and HEPA-filtered exhaust air for
environmental protection. (Source:
CDC) |
|
|
|
| Stability
/ Miscellaneous |
EXP: 24 hrs
(REFRIGERATE).
Indication: Treatment of cytomegalovirus (CMV)
retinitis.
Dosing:
Induction treatment: 5 mg/kg once weekly for 2
consecutive weeks.
Maintenance: 5 mg/kg administered once every 2
weeks
| Cidofovir
must be administered with intravenous saline
and probenecid prior to EACH cidofovir
infusion to reduce the incidence of
nephrotoxicity. |
Probenecid
dose: 2 grams 3 hours prior to cidofovir dose,
1 gram at 2 hours and 8 hours after completion
of the infusion (total of 4 grams probenecid).
Normal Saline hydration: Patients
should also receive 1 liter of normal saline
infused over 1-2 hours immediately prior to
each infusion of cidofovir. A second
liter may be administered if tolerated either
at the start of the VISTIDE infusion or
immediately afterfwards, and infused over a 1
to 3 hour period. |
Renal Dosing: Changes
in renal function during therapy: If the creatinine
increases by 0.3-0.4 mg/dL, reduce the cidofovir dose to
3 mg/kg; discontinue therapy for increases >/= 0.5
mg/dL or development of >/= 3+ proteinuria
Pre-existing renal impairment: Use is
contraindicated with serum creatinine >1.5 mg/dL,
calculated creatinine clearance <55 mL/minute, or
urine protein >/= 100 mg/dL (equivalent to >/= 2+
proteinuria)
Supplied: 75
mg/mL (5 mL) vial
|
| |
|
|
|
|
